Full-Time

Medical Director/Scientific Director

Neuroscience Clinical Development, Psychiatry

AbbVie

AbbVie

10,001+ employees

Global biopharmaceutical company developing medicines

Compensation Overview

$192.5k - $327k/yr

Livingston, NJ, USA

Hybrid

Three days on-site per week required.

Bachelor's, Master's, PhD

Category
Medical, Clinical & Veterinary (1)

Get referred to AbbVie

See people who can refer or advise you

Requirements
  • Medical Doctor (M.D.), Doctor of Osteopathy (D.O.), or non-US equivalent of M.D. degree with relevant therapeutic specialty in an academic or hospital environment.
  • Ability to run a clinical research study with appropriate supervision.
  • Ability to interact externally and internally to support global scientific and business strategy.
  • Must possess excellent oral and written English communication skills.
  • Bachelors degree in the sciences; advanced degree (e.g., MS, PhD) preferred.
Responsibilities
  • With appropriate supervision, manages the design and implementation of study protocols for a clinical development program in support of the overall Product Development Plan, based on strong medical and scientific principles, knowledge of compliance and regulatory requirements, AbbVie’s customers, markets, business operations, and emerging issues. Oversees project-related education of investigators, study site personnel, and AbbVie study staff.
  • Has responsibility for oversight of clinical studies, monitoring overall study integrity, and review, interpretation, and communication of accumulating data pertaining to safety and efficacy of the molecule. Along with Clinical Operations, is responsible for oversight of study enrollment and overall timelines for key deliverables. Responsible for assessment and reporting of serious adverse events per corporate policy and regulations for those protocols on which assigned.
  • Contributes to design, analysis, interpretation, and reporting of scientific content of protocols, Investigator Brochures, Clinical Study Reports, regulatory submissions and responses, and other program documents.
  • May serve on a Clinical Strategy Team as the clinical representative for the protocols for which the incumbent has responsibility. Contributes to the development of a rigorous, cross-functionally-aligned, vetted Clinical Development Plan in collaboration with matrix team members.
  • Participates in opinion leader interactions related to the disease area(s); partners with Medical Affairs, Commercial and other functions in these activities as required, consistent with corporate policies.
  • Stays abreast of professional information and technology through conferences, medical literature, and other available training, to augment expertise in the therapeutic area.
  • Responsible for understanding the regulatory requirements related to the clinical studies and global drug development and accountable for complying with those requirements. May be asked to contribute to regulatory responses and discussions.
  • Ensures adherence to Good Clinical Practices, pharmacovigilance standards, standard operating procedures and to all other quality standards in conducting research.
Desired Qualifications
  • Completion of a residency program strongly preferred.
  • Completion of a subspecialty fellowship in Psychiatry is desirable.
  • Clinical trial experience in the pharmaceutical industry, academia, or equivalent is preferred.
  • Knowledge of clinical trial methodology, regulatory and compliance requirements governing clinical trials and experience in the design of study protocols is desirable.
  • Advanced degree (e.g., MS, PhD) preferred.

AbbVie is a global biopharmaceutical company that develops and sells medicines to treat serious health conditions. Its portfolio spans immunology, oncology, virology, neuroscience, and aesthetics, with products designed to modulate the immune system, target disease pathways, or support medical aesthetics. AbbVie compounds its products through a heavy emphasis on research and development, investing billions to build a steady pipeline of new therapies. Its medicines are brought to market by selling to healthcare providers, hospitals, and clinics, and in some cases directly to patients via prescriptions. The company differentiates itself through a wide, globally distributed product line, substantial R&D investment, and a commitment to sustainability and patient care, including science-based targets. AbbVie’s goal is to improve patient outcomes by delivering effective treatments for unmet medical needs while pursuing long-term, responsible growth across healthcare markets.

Company Size

10,001+

Company Stage

IPO

Headquarters

North Chicago, Illinois

Founded

1888

Get referred to AbbVie

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • AbbVie raised 2026 revenue guidance to $67.6 billion after Q2 sales beat.
  • RINVOQ won July 2026 EU approvals for vitiligo and alopecia areata.
  • Apogee is expected to close in Q3 2026, deepening AbbVie’s pipeline.

What critics are saying

  • HUMIRA fell 36% in Q2 2026, and biosimilar erosion continues into 2027.
  • Epcoritamab missed its U.S. Phase 3 survival endpoint on July 23, 2026.
  • SKYRIZI’s 2033 patent cliff would gut AbbVie’s replacement for Humira if execution slips.

What makes AbbVie unique

  • AbbVie’s SKYRIZI and RINVOQ generated $8.8 billion in Q2 2026, replacing Humira.
  • The Apogee acquisition adds long-acting immunology assets for atopic dermatitis and asthma.
  • AbbVie’s scale, cash flow, and aesthetics franchise fund acquisitions and dividends.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Remote Work Options

Flexible Work Hours

Professional Development Budget

Growth & Insights and Company News

Headcount

6 month growth

3%

1 year growth

3%

2 year growth

3%
Yahoo Finance
Aug 15th, 2026
AbbVie shows strong cash flow margin of 34.8% but faces tepid revenue growth

AbbVie, the biopharmaceutical company spun off from Abbott Laboratories in 2013, has risen 9.7% to $249.64 per share over the past six months. The company generates $64.39 billion in revenue over the past 12 months, benefiting from significant economies of scale in its operations. AbbVie's free cash flow margin averaged 34.8% over the last five years, amongst the best in the healthcare sector. This strong cash generation enables reinvestment and capital returns to investors. However, the company's five-year annualised revenue growth of 3.7% remains tepid compared to sector peers. Despite this weakness, AbbVie's shares trade at 16.3 times forward price-to-earnings ratio. The company develops and markets medications for autoimmune diseases, cancer, neurological disorders, and other complex health conditions.

Yahoo Finance
Aug 13th, 2026
Genmab raises 2026 revenue guidance to $4.5B despite epcoritamab setback; AbbVie reports $17B Q2 revenue

Genmab and AbbVie confirmed on 23 July that their jointly developed bispecific antibody epcoritamab failed to meet its primary endpoint in a Phase 3 trial. The study evaluated epcoritamab monotherapy against chemoimmunotherapy in transplant-ineligible adults with relapsed/refractory diffuse large B-cell lymphoma. In the US, where overall survival was the sole primary endpoint, the trial did not demonstrate statistically significant improvement. Despite the setback, epcoritamab maintains its accelerated FDA approval. Both companies will review the full data set with regulators to determine next steps. Genmab reported H1 2026 revenue of $2.051 billion, up 25% year-over-year, raising full-year guidance to $4.325–$4.525 billion. AbbVie posted Q2 2026 net revenues of $16.99 billion, up 10.2%, driven by its immunology portfolio generating $8.79 billion.

Yahoo Finance
Aug 12th, 2026
AbbVie delivers 10.4% revenue growth and 34% margin but stock lags peers despite strong fundamentals

AbbVie's strong operational performance has not translated into stock gains matching its pharmaceutical peers. The drugmaker achieved 10.4% revenue growth and a 34% operating margin over the past year, ranking second among six key competitors. Despite these results, AbbVie's stock returned 30% over twelve months, trailing Merck's 67% and Johnson & Johnson's 54%. The disconnect appears rooted in market concerns about future competition. Analysts questioned management about competitive dynamics for key immunology drugs SKYRIZI and RINVOQ, which each grew sales 24%. The company trades at 70.1 times earnings but lacks the premium stock performance of peers. The market seems to be pricing in risks that AbbVie's high-performing drugs will face tougher competition, potentially eroding current growth rates and margins.

Manufacturing Digital
Aug 12th, 2026
Why Bristol Myers Squibb is investing $2.3bn in Texas.

Why Bristol Myers Squibb is investing $2.3bn in Texas. August 12, 2026 Bristol Myers Squibb is investing US$2.3bn in a new manufacturing facility in Houston, Texas, aiming to reinforce the US's pharmaceutical supply chain Bristol Myers Squibb (BMS) says it will invest US$2.3bn into a new manufacturing hub in Houston, Texas to boost its domestic pharmaceutical supply chain. The plan is part of the company's five year commitment to invest US$40bn in the US across research and development, domestic manufacturing and technology. Christopher Boerner, CEO of BMS, says: "As part of our US$40bn commitment to the United States, we're building the domestic manufacturing capabilities needed to deliver the next generation of medicines and support future scientific breakthroughs." What will the investment create? BMS says its new hub will allow the company to manufacture multiple types of medicine including small molecules, biologics and antibody drug conjugates. The campus will be located at Generation Park, spanning across 600,000 square feet, and aims to initially create around 500 skilled jobs. Building this new facility will allow the company to manufacture multiple types of medicine including small molecules, biologics and antibody drug conjugates. Initial plans are expected to bring construction between 2027 and 2030, during which BMS is expecting to create around 2,000 construction and other indirect jobs. BMS currently has seven manufacturing and commercial manufacturing facilities across the world. US pharmaceutical supply chain. According to research from the US Pharmacopeia in 2024, more than 50% of active pharmaceutical ingredient (API) production comes from Europe and India, while the US accounts for just 12%. The new BMS facility is expected to lower reliance on overseas production and develop the US supply chain. US Secretary of Commerce Howard Lutnick says: "Bristol Myers Squibb's US$2.3bn investment in Texas will create hundreds of high-paying jobs and strengthen our pharmaceutical supply chains, ensuring America is never reliant on foreign sources for critical medicines." In January 2026, Abbvie committed US$100bn towards domestic research, development and capital investments over a 10 year period. This funding has already seen some allocations, including across two API plants in Illinois, and another US$1.4bn for a manufacturing campus focusing on immunology, neuroscience and oncology products in North Carolina. Abbvie has also acquired a manufacturing facility in Arizona, where it designated US$175m to expand capacity for drug delivery devices. Company Portals

Yahoo Finance
Aug 11th, 2026
AbbVie acquires Apogee Therapeutics for $10.9B amid pipeline expansion

AbbVie has announced a $10.9 billion acquisition of Apogee Therapeutics in June 2026, aiming to strengthen its drug pipeline. The biopharmaceutical company reported FY 2025 revenue of nearly $61.2 billion, up roughly 8.6% year-on-year. Net income reached close to $4.2 billion, reflecting a net margin of approximately 6.9%, down from 7.6% the previous year. Free cash flow for the period was nearly $17.8 billion. CVS Health reported FY 2025 revenue of approximately $402.1 billion, representing growth of nearly 7.8%. The integrated healthcare provider serves around 37 million medical members and manages 1.9 billion prescriptions annually through its Health Services segment. Net income was close to $1.8 billion, yielding a net margin of roughly 0.4%, down from 1.2% in FY 2024.